Indaptus shares jump 10.38% after hours on $2.3M fundraising and positive Decoy20 safety data in Q3 results.

Indaptus Therapeutics (INDP) surged 10.38% in after-hours trading following the release of its third-quarter 2025 results and corporate update. The company completed the Safety Lead-In cohort of its Decoy20 and tislelizumab combination trial, with the Safety Review Committee deeming the regimen tolerable at the current dose. While efficacy results were mixed (three participants achieved stable disease, three experienced progression), the safety data provided a foundation for potential full enrollment. Additionally, Indaptus raised $2.3 million via an at-the-market facility in September 2025, extending its cash runway to the first quarter of 2026. These developments—combined with management’s emphasis on disciplined execution and upcoming data updates—likely drove investor optimism, despite the trial’s temporary pause pending further efficacy evaluations.